Overweight breast cancer survivors treated with tamoxifen may have higher risk for arm lymphedema
the ONA take:
Breast cancer survivors with a body mass index (BMI) >25 who report the use of tamoxifen therapy may be at increased risk for arm lymphedema, according to a recent study published in the Journal of Cancer Survivorship.
For the study, researchers analyzed data from 43 women breast cancer who reported physician-diagnosed lymphedema during follow-up of the long-term quality of life (LTQOL) study in order to investigate whether an association exists between treatment-related risk factors and development of arm lymphedema.
Results showed that tamoxifen had a non-significant, positive association with arm lymphedema, but type of surgery, radiation, or chemotherapy had no impact on the risk of lymphedema development. Researchers found that the risk for developing arm lymphedema was particularly higher among overweight and obese women with a BMI greater than 25 who were treated with tamoxifen.
"Lymphedema risk may be another indication to consider a weight reduction program in breast cancer survivors," the authors conclude.
Breast cancer survivors with a body mass index (BMI) >25 who report the use of tamoxifen therapy may be at increased risk for arm lymphedema.
- Earlier and Later Adult BMI Associated With Multiple Myeloma Risk
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- G-CSF May Help Preserve Fertility in Male Patients With Cancer
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Patients With HER2-enriched Subtype Benefit Most from Dual HER2 Blockade
- Scalp Cooling Reduces Risk of Chemotherapy-Induced Alopecia
- CRISPR Illustrates Progression of Normal Blood Cells to Leukemia, Precursor Diseases
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|